SCHEMBL7568319

SCHEMBL7568319

CC(C)C1CN(C(=O)OCC(Cl)(Cl)Cl)CC(OC(=O)OCC(Cl)(Cl)Cl)C1c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
DPP4 P27487 1/20 0.32
MITF O75030 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
POLB P06746 2/20 0.32
ALDH1A1 P00352 1/20 0.31
TP53 P04637 1/20 0.31
MDM2 Q00987 1/20 0.31
FAAH O00519 1/20 0.31
CYP3A4 P08684 2/20 0.30
PSEN1 P49768 2/20 0.30
PSEN2 P49810 2/20 0.30
APH1B Q8WW43 2/20 0.30
NCSTN Q92542 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6042198 0.92 CHRM2 (0.40) CHRM2CHRM4CHRM1CHRM3MITF
SCHEMBL7560345 0.90 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3DPP4
SCHEMBL6041390 0.82 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3NPSR1
SCHEMBL6042563 0.75 CHRM2 (0.37) CHRM2CHRM4CHRM1CHRM3NPSR1
SCHEMBL7553812 0.67 CHRM2 (0.36) CHRM2CHRM4CHRM1CHRM3HTT
SCHEMBL6042380 0.66 CHRM2 (0.35) CHRM2CHRM4CHRM1CHRM3HTT
SCHEMBL6042787 0.65 REN (0.45) KMT2AALDH1A1TP53MDM2
SCHEMBL6041482 0.65 MDM2 (0.36) TP53MDM2GRIN2B
SCHEMBL6042189 0.64 REN (0.43)
SCHEMBL6042700 0.62 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed